跳转至内容
Merck
CN

G-007

加巴喷丁标准液 CRM 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C9H17NO2
化学文摘社编号:
分子量:
171.24
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

certified reference material

Quality Level

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

SMILES string

NCC1(CCCCC1)CC(O)=O

InChI

1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)

InChI key

UGJMXCAKCUNAIE-UHFFFAOYSA-N

General description

加巴喷丁的商品名为 Neurontin ®、Nupentin 或 Gabarone,是一种抗惊厥药物,主要用于治疗癫痫、纤维肌痛和慢性神经性疼痛。该认证的 Snap-N-Spike ® 参比溶液适用于从法医分析、临床毒理学和疼痛处方监测到尿液药物检测的 GC/MS 或 LC/MS 应用。

Legal Information

Neurontin is a registered trademark of Warner-Lambert Co.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

Explore all of our products under 加巴喷丁标准液 CRM 溶液


signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

危险化学品

此项目有



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容

默克Supelco®标准物质不断推出或更新满足海关及法规要求的标准物质。每年我们约有上百种的新CRM或标准物质上市,在此我们尽可能多的列出满足海关及法规要求的标准物质。


Adam Bisaga et al.
Drug and alcohol dependence, 81(3), 267-274 (2005-09-20)
In laboratory animals, augmentation of GABA neurotransmission results in inhibition of cocaine self-administration and inhibition of reinstatement to cocaine-seeking behaviors. If parallel effects were observed in humans, GABA-ergic medication should be effective both in the abstinence-induction as well as in
Y Yu et al.
Clinical pharmacology and therapeutics, 94(4), 519-524 (2013-05-28)
To investigate the so-called "drift" with generic-generic drug substitution, a single-dose, four-way crossover comparative bioavailability study was performed involving 24 healthy subjects and three generic and one branded formulation of a tablet containing 800 mg gabapentin as test medication. The results
Mark P Jensen et al.
The Clinical journal of pain, 29(9), 770-774 (2013-02-02)
This study evaluated the long-term safety and tolerability of a gastroretentive formulation of gabapentin (G-GR) and its effect on weight gain in postherpetic neuralgia (PHN) patients participating in a 14-week, open-label extension to a 10-week double-blind study. Patients with PHN



全球贸易项目编号

货号GTIN
G-007-1ML04061833623053